Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Lexaria Bioscience Corp WT (LEXXW)

Lexaria Bioscience Corp WT (LEXXW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 230 K
  • Annual Income, $ -6,660 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade LEXXW with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 04/12/24
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6900 +10.14%
on 04/16/24
2.0700 -63.29%
on 03/26/24
-0.6000 (-44.12%)
since 03/22/24
3-Month
0.4550 +67.03%
on 02/29/24
2.5000 -69.60%
on 03/11/24
+0.0800 (+11.76%)
since 01/23/24
52-Week
0.0500 +1,420.00%
on 10/23/23
2.5000 -69.60%
on 03/11/24
+0.1681 (+28.40%)
since 04/20/23

Most Recent Stories

More News
Lexaria Bioscience (NASDAQ: LEXX) Focusing on GLP-1 Applications of DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that it will focus on glucagon-like peptide 1 (“GLP-1”) applications of its patented DehydraTECH(TM)...

LEXXW : 0.7600 (-17.39%)
LEXX : 2.24 (-1.10%)
Lexaria (NASDAQ: LEXX) CEO to Present at the Upcoming 14th Annual LD Micro Invitational

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced that it will be participating at the 14th Annual LD Micro Invitational at the Sofitel New York on...

LEXX : 2.24 (-1.10%)
LEXXW : 0.7600 (-17.39%)
Lexaria Bioscience (NASDAQ: LEXX) Names Experienced Corporate Finance Exec as New CFO

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has appointed a new chief financial officer. The company announced that, effective immediately, Nelson Cabatuan,...

LEXX : 2.24 (-1.10%)
LEXXW : 0.7600 (-17.39%)
Lexaria (NASDAQ: LEXX) Hires CRO for Second DehydraTECH-Powered GLP-1 Human Pilot Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced it has hired a contract research organization (“CRO”) to perform the company’s second DehydraTECH-powered...

LEXX : 2.24 (-1.10%)
LEXXW : 0.7600 (-17.39%)
Lexaria Bioscience (NASDAQ: LEXX) to Commence Diabetes and Weight Loss Animal Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced details for an eight-week animal study, WEIGHT-A24-1, to examine diabetes and weight loss effects...

LEXX : 2.24 (-1.10%)
LEXXW : 0.7600 (-17.39%)
Lexaria Bioscience (NASDAQ: LEXX) Reports Weight-Loss Results in Animal Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is reporting glucose reduction and weight-loss results in a testing of its wholly owned and patented DehydraTECH-CBD...

LEXX : 2.24 (-1.10%)
LEXXW : 0.7600 (-17.39%)
Lexaria Bioscience (NASDAQ: LEXX) Cleared to Commence HYPER-H23-1 Clinical Trial

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that the U.S. Food and Drug Administration (“FDA”) has confirmed the effectiveness of the company’s...

LEXX : 2.24 (-1.10%)
LEXXW : 0.7600 (-17.39%)
Lexaria Bioscience (NASDAQ: LEXX) Cleared to Commence HYPER-H23-1 Clinical Trial

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that the U.S. Food and Drug Administration (“FDA”) has confirmed the effectiveness of the company’s...

LEXX : 2.24 (-1.10%)
LEXXW : 0.7600 (-17.39%)
Lexaria Bioscience (NASDAQ: LEXX) Announces Closing of $3.6M Registered Direct Offering

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has closed on a registered direct offering. The offering included the purchase and sale of 1,558,443 shares of common...

LEXX : 2.24 (-1.10%)
LEXXW : 0.7600 (-17.39%)
Lexaria Bioscience (NASDAQ: LEXX) Reports on $3.6M Registered Direct Offering

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has entered into definitive agreements. The agreements are for the purchase and sale of 1,558,443 shares of common...

LEXX : 2.24 (-1.10%)
LEXXW : 0.7600 (-17.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar